文章：

PDK2和PDK3过表达反映急性髓系白血病预后不良

Overexpression of PDK2 and PDK3 reflects poor prognosis in acute myeloid leukemia 

原文发布日期：2018-12-22 

英文摘要：

Acute myeloid leukemia (AML) is a hematological malignancy characterized by the proliferation of immature myeloid cells, with impaired differentiation and maturation. Pyruvate dehydrogenase kinase (PDK) is a pyruvate dehydrogenase complex (PDC) phosphatase inhibitor that enhances cell glycolysis and facilitates tumor cell proliferation. Inhibition of its activity can induce apoptosis of tumor cells. Currently, little is known about the role of PDKs in AML. Therefore, we screened The Cancer Genome Atlas (TCGA) database for de novo AML patients with complete clinical information and PDK family expression data, and 84 patients were included for the study. These patients did not undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT). Univariate analysis showed that high expression of PDK2 was associated with shorter EFS (P = 0.047), and high expression of PDK3 was associated with shorter OS (P = 0.026). In multivariate analysis, high expression of PDK3 was an independent risk factor for EFS and OS (P < 0.05). In another TCGA cohort of AML patients who underwent allo-HSCT (n = 71), PDK expression was not associated with OS (all P > 0.05). Our results indicated that high expressions of PDK2 and PDK3, especially the latter, were poor prognostic factors of AML, and the effect could be overcome by allo-HSCT. 

摘要翻译： 

急性髓系白血病（AML）是一种以未成熟髓系细胞增殖、分化及成熟受阻为特征的血液系统恶性肿瘤。丙酮酸脱氢酶激酶（PDK）作为丙酮酸脱氢酶复合体（PDC）的磷酸酶抑制剂，可增强细胞糖酵解能力并促进肿瘤细胞增殖，抑制其活性可诱导肿瘤细胞凋亡。目前关于PDK家族在AML中的作用知之甚少。为此，我们筛选癌症基因组图谱（TCGA）数据库中具有完整临床信息及PDK家族表达数据的初诊AML患者，最终纳入84例未接受异基因造血干细胞移植（allo-HSCT）的患者进行研究。单因素分析显示PDK2高表达与较短的无事件生存期（EFS）相关（P=0.047），PDK3高表达与较短的总生存期（OS）相关（P=0.026）。多因素分析表明PDK3高表达是EFS与OS的独立危险因素（P<0.05）。在另一组接受allo-HSCT的TCGA AML患者队列（n=71）中，PDK表达与OS均无相关性（所有P>0.05）。我们的研究结果表明，PDK2和PDK3（尤其是后者）高表达是AML的不良预后因素，而allo-HSCT可克服其负面影响。

原文链接：

Overexpression of PDK2 and PDK3 reflects poor prognosis in acute myeloid leukemia